medigraphic.com
Instituto Nacional de Salud Pública

2020, Número 1

salud publica mex 2020; 62 (1)


Resistencia antimicrobiana y consumo de antibióticos en hospitales mexicanos

Miranda-Novales MG, Flores-Moreno K, López-Vidal Y, Rodríguez-Álvarez M, Solórzano-Santos F, Soto-Hernández JL, Ponce de León-Rosales S

Idioma: Inglés
Referencias bibliográficas: 15
Paginas: 42-49
Archivo PDF: 290.33 Kb.


RESUMEN

Objective. To establish the current situation of antimicrobial resistance and antibiotic consumption in Mexican hospitals. Materials and methods. Antimicrobial susceptibility data from blood and urine isolates were collected. Defined daily dose (DDD) of antibiotic consumption/100 occupied beds (OBD) was calculated. Results. Study period: 2016 and 2017. Of 4 382 blood isolates, E. coli and K. pneumoniae were most frequently reported, with antimicrobial resistance ›30% for most drugs tested, only for carbapenems and amikacin resistance were ‹20%. A. baumannii had antimicrobial resistance ›20% to all drugs. Resistance to oxacillin in S. aureus was 20%. From 12 151 urine isolates, 90% corresponded to E. coli; resistance to ciprofloxacin, cephalosporins and trimethoprim/ sulfamethoxazole was ›50%, with good susceptibility to nitrofurantoin, amikacin and carbapenems. Global median antimicrobial consumption was 57.2 DDD/100 OB. Conclusions. This report shows a high antimicrobial resistance level in Gram-negative bacilli and provides an insight into the seriousness of the problem of antibiotic consumption.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. O’Neill J. Tackling Drug-Resistant Infections Globally: final report and recommendations. The review on antimicrobial resistance. UK: Wellcome Trust, HM Government, 2016 [cited 2018 Dec 14]. Available from: https:// amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf

  2. Beyer P, Theuretzbacher U, Gottwalt S. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. Geneva: World Health Organization, 2017 [cited 2018 Dec 14]. Available from: http://apps.who.int/iris/bitstream/ handle/10665/258965/WHO-EMP-IAU-2017.11-eng.pdf;jsessionid= 79165B38AEFC4EB70CC4E510680E457A?sequence=1

  3. Hey SP, Kesselheim AS. Reprioritizing research activity for the post-antibiotic era: ethical, legal, and social considerations. Hastings Cent Rep. 2017;47(2):16-20. https://doi.org/10.1002/hast.685

  4. Weinstein MP, Patel JB, Campeau S, Eliopoulus GM, Galas MF, Humphries RM, et al. CLSI performance standards for antimicrobial susceptibility testing. CLSI supplement M100. 28th ed. Wayne PA: Clinical and Laboratory Standards Institute, 2018.

  5. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs [internet]. WHOCC [cited 2018 Dec 13]. Available from: https://www.whocc.no/atc_ddd_index/

  6. Gniadek TJ, Carroll KC, Simner PJ. Carbapenem-resistant non-glucose- fermenting Gram-negative bacilli: the missing piece to the puzzle. J Clin Microbiol. 2016;54(7):1700-10. https://doi.org/10.1128/JCM.03264-15

  7. Garza-González E, Morfín-Otero R, Mendoza-Olazarán S, Bocanegra- Ibarias P, FloresTreviño S, Rodríguez-Noriega E, et al. A snapshot of antimicrobial resistance in Mexico. Results from 47 centers from 20 states during a six-month period. PLoS ONE. 2019;14(3):e0209865. https://doi. org/10.1371/journal.pone.0209865

  8. Yang P, Chen Y, Jiang S, Shen P, Lu X, Xiao Y. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014. Antimicrob Resist Infect Control. 2018;7:137. https://doi.org/10.1186/ s13756-018-0430-1

  9. Seas C, Garcia C, Salles MJ, Labarca J, Luna C, Alvarez-Moreno C, et al. Staphylococcus aureus bloodstream infections in Latin America: results of a multinational prospective cohort study. J Antimicrob Chemother. 2018;73(1):212-22. https://doi.org/10.1093/jac/dkx350

  10. Abrego-Olvira E, Lagunes-Espinosa AL, Nudding-Martínez H, Peralta- Pedrero ML, Quiroz-Cisneros J, Sánchez-Ambriz S. Diagnóstico y tratamiento de la infección aguda, no complicada del tracto urinario de la mujer. Guía de Práctica Clínica. Mexico: Secretaría de Salud, 2009 [cited 2018 Dec 13]. Available from: http://www.cenetec.salud.gob.mx/descargas/ gpc/CatalogoMaestro/077_GPC_InfAgnocompdeltractourinariomujer/ tractourinario_de_la_mujer.pdf

  11. McNulty C. Summary of antimicrobial prescribing guidance – managing common infections. London: Public Health England, 2018 [cited 2019 June 29]. https://assets.publishing.service.gov.uk/government/uploads/system/ uploads/attachment_data/file/777505/Common_Infect_-_PHE_context_ references_and_rationale_Feb_2019.pdf

  12. Bitterman R, Hussein K, Leibovici L, Carmeli Y, Paul M. Systematic review of antibiotic consumption in acute care hospitals. Clin Microbiol Infect. 2016;22:561.e7-19. https://doi.org/10.1016/j.cmi.2016.01.026

  13. Klein EY, Van Boeckeld TP, Martinez EM, Pant J, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018;115(15):E3463-70. https://doi.org/10.1073/pnas.1717295115

  14. Ponce de Leon A, Rodríguez-Noriega E, Morfín-Otero R, Cornejo- Juárez DP, Tinoco JC, Martínez-Gamboa A, et al. Antimicrobial susceptibility of Gram-negative bacilli isolated from intra-abdominal and urinary-tract infections in Mexico from 2009 to 2015: Results from the study for monitoring antimicrobial resistance trends (SMART). PLoS One. 2018;13(6):e0198621. https://doi.org/10.1371/journal.pone.0198621

  15. Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018;6(6):e619-29. https://doi.org/10.1016/S2214- 109X(18)30186-4




2020     |     www.medigraphic.com